# Hetrombopag for Low/Intermediate-1 Risk MDS With Thrombocytopenia

> **NCT05024877** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 50 (estimated)

## Conditions studied

- MDS

## Interventions

- **DRUG:** Hetrombopag
- **DRUG:** Stanozolol Tablets

## Key facts

- **NCT ID:** NCT05024877
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-01
- **Primary completion:** 2023-10-01
- **Final completion:** 2023-12-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2021-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05024877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05024877, "Hetrombopag for Low/Intermediate-1 Risk MDS With Thrombocytopenia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05024877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*